Meloxicam, a selective inhibitor of cyclooxygenase 2, was tested to determine its ability to modulate hematopoiesis and to influence survival of mid-lethally gamma-irradiated mice. A single dose of meloxicam (20 mg/kg) administered to mice intraperitoneally 1 h before irradiation was shown to enhance serum levels of granulocyte colony-stimulating factor (G-CSF) during the first 24 h after irradiation, to elevate numbers of granulocytic precursor cells in bone marrow and granulocyte counts in peripheral blood on day 10 after irradiation, and to increase 30-day survival of these mice. The results provide new evidence for the protective ability of meloxicam administration to mice irradiated with mid-lethal doses and contribute to the understanding of the mechanisms of this meloxicam action by drawing attention to the possible role of increased endogenous G-CSF production.

Laboratory of Experimental Hematology Institute of Biophysics v v i Academy of Sciences of the Czech Republic Brno Czech Republic

References provided by Crossref.org

Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome

Impaired post-irradiation survival of cyclooxygenase-2-deficient mice

Hematological profile of untreated or ionizing radiation-exposed cyclooxygenase-2-deficient mice

Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review

Granulocyte colony-stimulating factor in the treatment of acute radiation syndrome: a concise review

Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ-irradiated mice

Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: a review